136 related articles for article (PubMed ID: 33875305)
1. Reply to Riuko Ohashi, Arndt Hartmann, Holger Moch, and Guido Martignoni's Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Two-, Three-, or Four-tiered Grading of Chromophobe Renal Cancer: That's the Question!
Avulova S; Cheville JC; Lohse CM; Thompson RH; Potretzke AM
Eur Urol; 2021 Jul; 80(1):e19. PubMed ID: 33875305
[No Abstract] [Full Text] [Related]
2. Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Two-, Three-, or Four-tiered Grading of Chromophobe Renal Cancer: That's the Question!
Ohashi R; Hartmann A; Martignoni G; Moch H
Eur Urol; 2021 Jul; 80(1):e17-e18. PubMed ID: 33934927
[No Abstract] [Full Text] [Related]
3. Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Should Chromophobe Renal Cell Carcinoma Be Graded?
Delahunt B; Samaratunga H; Egevad L
Eur Urol; 2021 May; 79(5):e141-e142. PubMed ID: 33612375
[No Abstract] [Full Text] [Related]
4. Reply to Brett Delahunt, Hemamali Samaratunga, Lars Egevad's Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31. Should Chromophobe Renal Cell Carcinoma Be Graded?
Avulova S; Cheville JC; Lohse CM; Potretzke AM
Eur Urol; 2021 May; 79(5):e143-e144. PubMed ID: 33637366
[No Abstract] [Full Text] [Related]
5. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
Avulova S; Cheville JC; Lohse CM; Gupta S; Potretzke TA; Tsivian M; Thompson RH; Boorjian SA; Leibovich BC; Potretzke AM
Eur Urol; 2021 Feb; 79(2):225-231. PubMed ID: 33172723
[TBL] [Abstract][Full Text] [Related]
6. Re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting Functional Outcomes After Partial and Radical Nephrectomy. Eur Urol 2019;75:766-72: Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
Takahashi T
Eur Urol; 2019 Sep; 76(3):e65-e66. PubMed ID: 31164251
[No Abstract] [Full Text] [Related]
7. Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766-72. Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
Bhindi B; Lohse CM; Schulte PJ; Mason RJ; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2019 Sep; 76(3):e67-e68. PubMed ID: 31167750
[No Abstract] [Full Text] [Related]
8. Re: Outcomes following partial nephrectomy by tumor size P. L. Crispen, S. A. Boorjian, C. M. Lohse, T. S. Sebo, J. C. Cheville, M. L. Blute and B. C. Leibovich J Urol 2008; 180: 1912-1917.
Cimen HI; Serefoglu EC; Balbay MD
J Urol; 2009 Sep; 182(3):1232; author reply 1232. PubMed ID: 19625039
[No Abstract] [Full Text] [Related]
9. Reply to Aaron M. Potretzke, Jeffrey A. Larson and Sam B. Bhayani's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9.
Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
Eur Urol; 2015 Feb; 67(2):e21-2. PubMed ID: 25257031
[No Abstract] [Full Text] [Related]
10. Reply to Pascal Mouracade's letter to the editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9.
Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
Eur Urol; 2015 Oct; 68(4):e84-5. PubMed ID: 26058957
[No Abstract] [Full Text] [Related]
11. Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73.
Marconi L; Lam TB; Bex A; Ljungberg B; Volpe A
Eur Urol; 2016 Jun; 69(6):e119-20. PubMed ID: 26776936
[No Abstract] [Full Text] [Related]
12. Reply to Homayoun Zargar, Rafael F. Coelho and Jihad H. Kaouk's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9.
Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
Eur Urol; 2015 Feb; 67(2):e24-5. PubMed ID: 25257032
[No Abstract] [Full Text] [Related]
13. Reply to Lorenzo Marconi, Karim Bensalah, and Axel Bex's Letter to the Editor re: Paul C.M.S. Verhagen, Egbert R. Boevé. The European Association of Urology Guideline on Renal Cell Carcinoma (RCC) is Not Concise in its Recommendation to Perform Partial Nephrectomy in T1b RCC. Eur Urol 2019;76:136-7.
Verhagen PCMS; Boevé ER
Eur Urol; 2019 Jul; 76(1):e14. PubMed ID: 30910344
[No Abstract] [Full Text] [Related]
14. Reply to Pranav Sharma, Asad Sawar and Philippe Spiess' letter to the editor re: re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular extraction of caval tumor thrombus to facilitate minimally invasive cytoreductive nephrectomy for metastatic kidney cancer. Eur Urol 2015;68:167-8.
Rogers CG; Barod R; Schwartz S; Menon M
Eur Urol; 2015 Oct; 68(4):e81. PubMed ID: 26004799
[No Abstract] [Full Text] [Related]
15. Reply to Steven C. Campbell, Chalairat Suk-Ouichai, and Yun-Lin Ye's Words of Wisdom re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. Antonelli A, Minervini A, Sandri M, et al. Eur Urol 2018;74:661-7 and 2019;75:198.
Antonelli A; Minervini A; Capitanio U
Eur Urol; 2019 Jul; 76(1):e17-e18. PubMed ID: 30711331
[No Abstract] [Full Text] [Related]
16. Reply to Yang Zhao, Wenda Wang, and Yushi Zhang's Letter to the Editor re: Sounak Gupta, Christine M. Lohse, Ross Rowsey, et al. Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. Eur Urol 2022;81:229-33.
Gupta S; Lohse CM; Jimenez RE; Cheville JC
Eur Urol; 2022 Oct; 82(4):e117. PubMed ID: 35810047
[No Abstract] [Full Text] [Related]
17. Re: Todd M. Morgan, Dominic Tang, Kelly L. Stratton, et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 2011;59:923-8. Re: Umberto Capitanio, Francesco Montorsi. Does preoperative nutritional status affect survival in renal cell carcinoma? The debate continues. Eur Urol 2011;59:929-30.
Brookman-May S; Burger M; Wieland WF; May M
Eur Urol; 2011 Nov; 60(5):e45-6; author reply e47. PubMed ID: 21820239
[No Abstract] [Full Text] [Related]
18. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma.
Santoni M; Montironi R; Battelli N; Massari F
Eur Urol; 2019 Mar; 75(3):e64-e66. PubMed ID: 30391082
[No Abstract] [Full Text] [Related]
19. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
[No Abstract] [Full Text] [Related]
20. Re: outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy: R. H. Breau, P. L. Crispen, R. E. Jimenez, C. M. Lohse, M. L. Blute and B. C. Leibovich J Urol 2010; 183: 903-908.
Cimen HI; Canda AE; Balbay MD
J Urol; 2010 Nov; 184(5):2212; author reply 2212-3. PubMed ID: 20864129
[No Abstract] [Full Text] [Related]
[Next] [New Search]
